Results 41 to 50 of about 1,690 (152)

Evidence‐Based Clinical Practice Guidelines for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) 2026

Hepatology Research, Volume 56, Issue 6, Page 887-902, June 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, with an increasing number of patients progressing to cirrhosis and hepatocellular carcinoma (HCC). Early identification of individuals at high risk for advanced fibrosis is essential for preventing liver‐related ...
Norio Akuta, Tomomi Kogiso, Kenichi Ikejima, Motoyuki Otsuka, Takumi Kawaguchi, Miwa Kawanaka, Hirokazu Takahashi, Nobuharu Tamaki, Hayato Nakagawa, Hayato Hikita, Hideki Fujii, Kanji Yamaguchi, Masato Yoneda, Kazuyoshi Kon, Akira Uchiyama, Yuya Seko, Sadatsugu Sakane, Ryuta Shigefuku, Naoto Fujiwara, Michihiro Iwaki, Takashi Kobayashi, Takuya Adachi, Yasuto Takeuchi, Tsubasa Tsutsumi, Dan Nakano, Kaoru Shibayama, Noriyo Urata, Hisamitsu Miyaaki, Hidekatsu Kuroda, Masahiro Koseki, Hirohito Sone, Yasuhiro Matsubayashi, Keisuke Kakisaka, Atsushi Takai, Kazuo Notsumata, Masataka Seike, Yoshiyuki Takei, Yoshifumi Takeyama, Susumu Eguchi, Sumio Watanabe, Hajime Isomoto, Hiroshi Yotsuyanagi, Takao Itoi, Tetsuo Takehara, Satoshi Mochida   +44 more
wiley   +1 more source

Preclinical evaluation of new drug-drug interactions of lomitapide: A proposal for novel mechanism of interaction associated with lipid metabolic changes.

Biochemical Pharmacology
Lomitapide, a microsomal triglyceride transfer protein inhibitor, is a lipid-lowering drug that inhibits chylomicron formation in enterocytes and very low-density lipoprotein (VLDL) formation in the liver.
Sayo M Ito, Yoshihide Yamanashi, Hiroshi Suzuki, T. Takada   +3 more
semanticscholar   +1 more source

Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

Pharmacy, 2018
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most.
Donatella Zodda, Rosario Giammona, Silvia Schifilliti   +2 more
doaj   +1 more source

Small Molecule Kinase Inhibitors with In Vitro β‐Hematin Formation and Plasmodium falciparum Protein Kinase G Inhibitory Activity Identified Using Machine Learning

ChemMedChem, Volume 21, Issue 3, 12 February 2026.
A random forest machine learning model was used in combination with molecular docking to predict activity of small molecule kinase inhibitors against two crucial antimalarial targets, namely hemozoin crystallization and Plasmodium falciparum protein kinase G. Derazantinib shows most promise as a dual inhibitor.
Jessica L. Thibaud, Nicolaas Salomane, Sarah Harries, Kathryn J. Wicht, Lauren B. Coulson, David Kuter, Kelly Chibale, Katherine A. de Villiers   +7 more
wiley   +1 more source

Current Role of Lipoprotein Apheresis in the Treatment of High-Risk Patients

Journal of Cardiovascular Development and Disease, 2018
Lipoprotein apheresis (LA) is a therapeutic approach to save the lives of patients who are at an extremely high risk of developing cardiovascular events (CVE), especially after all other therapeutic options were not tolerated, or appeared not to be ...
Ulrich Julius
doaj   +1 more source

The High Price of Interrupted Follow‐Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia—A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder, primarily resulting from mutations in LDLR, APOB, and PCSK9 genes. These mutations cause persistently high levels of low‐density lipoprotein cholesterol (LDL‐C), predisposing affected individuals to premature atherosclerotic cardiovascular disease (ASCVD ...
Parham Dastjerdi, Mahdieh Aghababaei, Reza Nikfar, Maryam Aghakouchakzadeh, Reza Mohseni‐Badalabadi, Kaveh Hosseini   +5 more
wiley   +1 more source

Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site

Pharmaceutics, 2022
P38α mitogen-activated protein kinase (p38α MAPK), one of the p38 MAPK isoforms participating in a signaling cascade, has been identified for its pivotal role in the regulation of physiological processes such as cell proliferation, differentiation ...
Utid Suriya, Panupong Mahalapbutr, Thanyada Rungrotmongkol   +2 more
doaj   +1 more source

Low Cholesterol due to APOB Variants: Exploring the Balance Between Liver and Cardiovascular Risk

Liver International, Volume 46, Issue 2, February 2026.
ABSTRACT Background & Aims Lifelong APOB gene inactivation lowers LDL‐C and cardiovascular risk, but impairs hepatic lipoprotein export, predisposing to chronic liver disease (CLD). The extent to which common steatogenic factors modulate this risk remains unclear.
Alessia Di Costanzo, Ilaria Pirona, Silvia Buonaiuto, Stella Covino, Carlo Maiorca, Simone Bini, Daniele Tramontano, Ilenia Minicocci, Francesco Baratta, Vincenza Colonna, Allegra Via, Laura D'Erasmo, Marcello Arca   +12 more
wiley   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, Volume 6, Issue 1, January 2026.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

Stimulator of interferon genes (STING)‐activating nanomedicines: Translating innate immune modulation into effective therapy for triple‐negative breast cancer

Clinical and Translational Medicine, Volume 16, Issue 1, January 2026.
Graphical representation of STING‐activated nanomedicines is for effective treatment of triple‐negative breast cancer. Abstract Triple‐negative breast cancer (TNBC), marked by profound immunosuppressive complexity, poses a critical challenge in therapy due to the absence of hormone receptors in its phenotype, making it unavailable for conventional ...
Harshita Singhai, Taha Alqahtani, Humood Al Shmrany, Garima Gupta, Umesh Kumar Patil, Amirhossein Sahebkar, Prashant Kesharwani   +6 more
wiley   +1 more source